ferumoxides
Trade name: feridex I.V.
Small moleculeapproved
Approved
Aug 30, 1996
Clinical trial activity
6 trials · 6 clinical orgs · 1 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00453817)
Timeline
1990s
- Aug 30, 1996
AMAG Pharmaceuticals, Inc. — Earliest FDA Approval
- Aug 30, 1996
AMAG Pharmaceuticals, Inc. — NDA Secondary Org
- Aug 30, 1996
AMAG Pharmaceuticals, Inc. — NDA Organization
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Diagnostic
- IronSupplementation
Iron supplementation
Approval history
- approvedAug 30, 1996
Chemistry & pharmacology
Loading structure…
SMILES
[O--].[O--].[O--].[O--].[Fe++].[Fe+3].[Fe+3]- Mol. weight
- 231.533 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- NCATSG6N3J05W84 ↗
- ChEMBLCHEMBL2108388 ↗
- ChEMBLCHEMBL1201502 ↗
Also known as
- ami25
- ami 25
- ami-25
- ami-25
- aquamag100
- carboxydextran-coated superparamagnetic iron oxide
- dextran-coated spio
- dextran-coated superparamagnetic iron oxide
- endorem
- endorem
- endorem
- feridex
- feridex
- feridex
- feridex
- feridex iv
- ferucarbotran
- ferucarbotran
- ferucarbotran
- ferucarbotran
- ferumoxides
- ferumoxides
- ferumoxides
- ferumoxides
- ferumoxides
- ferumoxides
- ferumoxides non-stoichiometric magnetite
- resovist
- sh u 555a
- shu 555a
- shu-555a
- win 39996
- zk-132281
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03458130 | Phase 2 | Apr 27, 2018 | Eidos Therapeutics, Inc. |
| NCT05959590 | Phase 1 | Feb 12, 2014 | University of New Mexico |
| NCT01169935 | N/A | Jul 1, 2010 | British Heart Foundation, University of Edinburgh |
| NCT00972946 | N/A | Sep 1, 2009 | University of Edinburgh |
| NCT00886444 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2009 | University of Tuebingen |
| NCT00453817 | Phase 1 | Jun 1, 2005 | University of Geneva |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Edinburgh | Academic/Hospital | 2 | 2 | 1 | 2009 |
| British Heart Foundation | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Eidos Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2018 |
| University of Geneva | Academic/Hospital | 1 | 1 | 1 | 2005 |
| University of New Mexico | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Tuebingen | Academic/Hospital | 1 | 1 | 1 | 2009 |
6 organizations
Page 1 / 1
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AMAG Pharmaceuticals, Inc. | For profit | NDA2 | Aug 30, 1996 |
| AMAG Pharmaceuticals, Inc. | For profit | NDA | Aug 30, 1996 |